Keywords: shire, sales, up, pre-adderall, demise, specialty, pharmaceuticals
Shire sales up 20% pre-Adderall demise
Article | 01 May 2009
Specialty pharmaceuticals firm Shire has reported a 20% increase in first-quarter 2009 product sales, which reached $756.0 million, generating non-GAAP operating income of $327.0 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
